ICU Medical (NASDAQ:ICUI) Now Covered by Piper Sandler

Equities research analysts at Piper Sandler started coverage on shares of ICU Medical (NASDAQ:ICUI) in a research note issued on Friday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $145.00 price target on the medical instruments supplier’s stock. Piper Sandler’s price objective indicates a potential upside of 16.77% from the stock’s current price.

Several other brokerages have also issued reports on ICUI. Raymond James Financial cut their price target on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. KeyCorp cut their price target on ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a report on Monday, April 21st. Finally, Wall Street Zen downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $179.00.

ICU Medical Trading Up 1.0%

Shares of ICU Medical stock traded up $1.2150 on Friday, hitting $124.1750. 55,626 shares of the company’s stock traded hands, compared to its average volume of 266,131. The company has a fifty day moving average of $127.94 and a two-hundred day moving average of $137.73. The company has a market capitalization of $3.07 billion, a price-to-earnings ratio of -81.69 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. ICU Medical has a one year low of $107.00 and a one year high of $196.26.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.66. The business had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The company’s quarterly revenue was down 8.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, sell-side analysts expect that ICU Medical will post 4.11 earnings per share for the current year.

Insiders Place Their Bets

In other ICU Medical news, COO Christian B. Voigtlander sold 4,985 shares of ICU Medical stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total transaction of $640,572.50. Following the completion of the sale, the chief operating officer owned 6,088 shares of the company’s stock, valued at $782,308. The trade was a 45.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Vivek Jain purchased 21,929 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were purchased at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the purchase, the chief executive officer owned 130,149 shares of the company’s stock, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 14,889 shares of company stock valued at $1,933,186 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several hedge funds have recently added to or reduced their stakes in ICUI. Xponance Inc. increased its holdings in shares of ICU Medical by 5.3% in the first quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier’s stock worth $238,000 after buying an additional 86 shares during the period. LPL Financial LLC grew its holdings in shares of ICU Medical by 2.0% during the 4th quarter. LPL Financial LLC now owns 4,816 shares of the medical instruments supplier’s stock worth $747,000 after acquiring an additional 93 shares during the period. Moody National Bank Trust Division boosted its position in shares of ICU Medical by 0.9% in the 2nd quarter. Moody National Bank Trust Division now owns 10,751 shares of the medical instruments supplier’s stock worth $1,421,000 after purchasing an additional 93 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of ICU Medical by 4.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock worth $325,000 after purchasing an additional 107 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.